ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ニトラゼパム

Nitrazepam

HCID 4506
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
146-22-5
標準SMILES
O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
InChIKey
KJONHKAYOJNZEC-UHFFFAOYSA-N
分子式
C15H11N3O3
平均分子量
281.27 g/mol
単同位体質量
281.08004122

概要

Nitrazepam is a 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome). It has a role as an anticonvulsant, a sedative, a drug metabolite, a GABA modulator and an antispasmodic drug. It is a 1,4-benzodiazepinone and a C-nitro compound.

名称と識別子

優先名称
Nitrazepam
IUPAC
7-nitro-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
現地名
ニトラゼパム
英語名
Nitrazepam
分子式
C15H11N3O3
分子量
281.27

名称と別名

nitrazepamBenzalin146-22-5MogadonRadedormApodormCalsminEunoctinNeozepamNeuchlonicNitradosSonebon
名称をさらに表示
ヒルスカミンソムニット1,3-ジヒドロ-7-ニトロ-5-フェニル-2H-1,4-ベンゾジアゼピン-2-オンキルスレムモガダンエピネルボン1,3-ジヒドロ-7-ニトロ-5-(フェニル)-2H-1,4-ベンゾジアゼピン-2-オンベンザリン5-(フェニル)-7-ニトロ-1H-1,4-ベンゾジアゼピン-2(3H)-オンドルミカムニトレンパックスナムボンニジアゼポンネウクロニックソミトランヒプサルモガドンミチジンアポドルムNtz1,3-dihydro-7-nitro-5-phenyl-2h-4-benzodiazepin-2-onela1Nitrazepam (CRM)1,3-dihydro-7-nitro-5-phenyl-1,4-benzodiazepin-2-one7-Nitro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one7-Nitro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-oneLA 1Eatan
HipsalImesonRemnosSuremSomitranSonnolinTrazeninUnisomnia

物性

構造計算による物性

XLogP
2.2
極性表面積
87.3 Ų
水素結合供与体数
1
水素結合受容体数
4
回転可能結合数
1
重原子数
21
形式電荷
0
複雑度
452

実験および物理化学的性質

Drugs · 6 件

DEA NFLIS-Drug Category -> Benzodiazepines

DEA Schedule IV Controlled Substance -> Depressants

Pharmaceuticals -> Benzodiazepines

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds

LogP · 2 件

2.25

2.06

Solubility · 2 件

2.99e-02 g/L

>42.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines

Pharmaceuticals

Melting Point225 °C
Physical DescriptionSolid
Collision Cross Section · 2 件

166.3 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated]

163.6 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

物理化学的性質

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 49 reports by companies from 3 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory Information · 2 件

DEA schedule IV controlled substance

Nitrazepam: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (100%)

毒性情報

Treatment · 1 件

General supportive measures should be employed, along with intravenous fluids, and an adequate airway maintained. Hypotension may be combated by the use of norepinephrine or metaraminol. Dialysis is of limited value. Flumazenil (Anexate) is a competitive benzodiazepine receptor antagonist that can be used as an antidote for benzodiazepine overdose. In particular, flumazenil is very effective at reversing the CNS depression associated with benzodiazepines but is less effective at reversing respiratory depression. Its use, however, is controversial as it has numerous contraindications. It is contraindicated in patients who are on long-term benzodiazepines, those who have ingested a substance that lowers the seizure threshold, or in patients who have tachycardia or a history of seizures. As a general rule, medical observation and supportive care are the mainstay of treatment of benzodiazepine overdose. Although benzodiazepines are absorbed by activated charcoal, gastric decontamination with activated charcoal is not beneficial in pure benzodiazepine overdose as the risk of adverse effects often outweigh any potential benefit from the procedure. It is recommended only if benzodiazepines have been taken in combination with other drugs that may benefit from decontamination. Gastric lavage (stomach pumping) or whole bowel irrigation are also not recommended.

化学と産業

薬理情報

ATC Code · 3 件

N05CD02

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Nitrazepam is a type of benzodiazepine drug. It is a powerful hypnotic drug which possesses strong sedative, anxiolytic, amnestic, anticonvulsant, and skeletal muscle relaxant properties. Nitrazepam shortens the time required to fall asleep and lengthens the duration of sleep. It is also useful for the management of myoclonic seizures.

Mechanism of Action · 1 件

Nitrazepam belongs to a group of medicines called benzodiazepines. This drug affects central benzodiazepine receptors, which are associated with inhibitory GABA (gamma amino butyric acid)receptors, leading to enhanced GABA binding activity. GABA is a major neurotransmitter in the brain, which causes somnolence, relaxation of muscles, a decrease in anxiety and general central nervous system depression. Nitrazepam has anticonvulsant properties that may be attributed to its ability to bind to voltage-dependent sodium channels. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.

Biological Half-Life15-38 hours (mean elimination half life 26 hours).
Metabolism/MetabolitesIt is long acting, is lipophilic and is metabolised hepatically via oxidative pathways. [Wikipedia] Half Life: 15-38 hours (mean elimination half life 26 hours).
MeSH Pharmacological Classification · 4 件

Drugs used to prevent SEIZURES or reduce their severity.

Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.

Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here.

Substances that do not act as agonists or antagonists but do affect the GAMMA-AMINOBUTYRIC ACID receptor-ionophore complex. GABA-A receptors (RECEPTORS, GABA-A) appear to have at least three allosteric sites at which modulators act: a site at which BENZODIAZEPINES act by increasing the opening frequency of GAMMA-AMINOBUTYRIC ACID-activated chloride channels; a site at which BARBITURATES act to prolong the duration of channel opening; and a site at which some steroids may act. GENERAL ANESTHETICS probably act at least partly by potentiating GABAergic responses, but they are not included here.

関連反応

7 件
反応記録を作成
HRID 135958 の反応式
HRID 135958反応物として
HRID 214363 の反応式
HRID 214363反応物として
HRID 697239 の反応式
HRID 697239反応物として
HRID 865711 の反応式
HRID 865711反応物として
HRID 1729599 の反応式
HRID 1729599反応物として
HRID 1973059 の反応式
HRID 1973059生成物として
HRID 2418314 の反応式
HRID 2418314反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
146-22-5
PubChem CID
4506
DTXSID
DTXSID5023372
ChEMBL
CHEMBL13209
ChEBI
CHEBI:7581
UNII
9CLV70W7HS
EC Number
205-665-2
Nikkaji
J2.956D
融点
223 · 223-227C
沸点
423.94 °C · 423.94°C (rough estimate)
比重(密度)
1.2309 · 1.2309 (rough estimate)
屈折率
1.57 · 1.5700 (estimate)
闪点
2 ℃ · 2℃
貯蔵温度
-20 °C · Controlled Substance, -20°C Freezer
溶解性
水にほとんど溶けず、エタノールにわずかに溶けます (96%)。
酸解離定数(Pka)
2.9 · pKa 2.90 ± 0.05;10.39±0.04(H2O,t =25,I=0.015(KCl))(Approximate)
水溶解度
3.93 mg/L · 3.93mg/L(25℃)
主な用途
医薬品(低分子化合物)
InChI
1S/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)
InChIKey
KJONHKAYOJNZEC-UHFFFAOYSA-N
SMILES
[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3)c2c1
CAS データベース
146 · 146-22-5(CAS DataBase Reference)
NISTの化学物質情報
Nitrazepam(146-22-5)
EPAの化学物質情報
2 H-1,4-Benzodiazepin-2-one, · 2H-1,4-Benzodiazepin-2-one, 1,3-dihydro-7-nitro-5-phenyl- (146-22-5)

化学的性質

化学的特性Pink Solid

Health Effects · 1 件

They cause slurred speech, disorientation and "drunken" behavior. They are physically and psychologically addictive. May cause a potentially dangerous rash that may develop into Stevens Johnson syndrome, an extremely rare but potentially fatal skin disease.

Exposure RoutesBioavailability is 53-94% following oral administration.
Toxicity Summary · 1 件

Nitrazepam belongs to a group of medicines called benzodiazepines. It acts on benzodiazepine receptors in the brain which are associated with the GABA receptors causing an enhanced binding of GABA (gamma amino butyric acid) to GABAA receptors. GABA is a major inhibitory neurotransmitter in the brain, involved in inducing sleepiness, muscular relaxation and control of anxiety and fits, and slows down the central nervous system. The anticonvulsant properties of nitrazepam and other benzodiazepines may be in part or entirely due to binding to voltage-dependent sodium channels rather than benzodiazepine receptors. Sustained repetitive firing seems to be limited by benzodiazepines effect of slowing recovery of sodium channels from inactivation.

Signs and Symptoms · 1 件

Nitrazepam is a drug which is very frequently involved in drug intoxication, including overdose. Nitrazepam overdose may result in stereotypical symptoms of benzodiazepine overdose including intoxication, impaired balance, slurred speech. In cases of severe overdose this may progress to a comatose state with the possibility of death.

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Nitrazepam

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
rtecs
DF2450000
ridadr
3249
毒性
LD50 orally in rats: 825 ±80 mg/kg (Randall)
risk_code
22-36-20/21/22-11
hazard_code
Xn,F
safety_code
36/37/39-36/37-16
hazard_class
6.1(b)
packing_group
III
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids
Absorption, Distribution and ExcretionBioavailability is 53-94% following oral administration.
Cellular LocationsMembrane

用途と製造

Uses · 2 件

Use (kg; approx.) in Germany (2009): ?100

Used to treat short-term sleeping problems (insomnia), such as difficulty falling asleep, frequent awakenings during the night, and early-morning awakening.

Use ClassificationPharmaceuticals
応用分野 · 5 件

解説1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one.C15H11N3O3(281.27).ニトラゼパムは,2-アミノ-5-ニトロベンゾフェノンとグリシンから合成される.黄色の結晶.融点224~226 ℃.λmax 277.5 nm(0.1 mol L-1 硫酸).水に不溶,クロロホルム,アセトン,エタノールに可溶.睡眠鎮静剤,抗てんかん薬として使用される.LD50 1800 mg/kg(マウス,経口).森北出版「化学辞典(第2版)

用途ベンゾジアゼピン系化合物で す。GABA 受容体に作用し、中枢神経抑制作 用を示します。作用時間は中時間です。

用途ベンゾジアゼピン系化合物で す。GABA受容体に作用し、中枢神経抑制作 用を示します。作用時間は中時間です。

用途神経化学研究用。

使用Anticonvulsant; hypnotic. Controlled substance (depressant)

上流・下流製品情報

上流原料

2-クロロアセトアミドクロロアセチルクロリド2-アミノ-5-ニトロベンゾフェノン4-クロロアニリンヘキサメチレンテトラミンベンゾイルクロリド硝酸グリシンエチル塩酸塩2-アミノベンゾフェノンAcetamide, 2-amino-N-(2-benzoyl-4-nitrophenyl)-5-(フェニル)-1H-1,4-ベンゾジアゼピン-2(3H)-オンN-(2-ベンゾイル-4-ニトロフェニル)-2-クロロアセトアミドトルエン-4-スルホン酸
補足説明 · 1 件

定義ChEBI: A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the trea ment of epileptic spasms in infants (West's syndrome).